3 February 2022PatentsAlex Baldwin

Hirshfeld defends IPR review authority under Arthrex

The acting director of the US Patent and Trademark Office (USPTO) Andrew Hirshfeld has defended his right to review final Patent Trial and Appeal Board (PTAB) decisions under Arthrex.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Patents

Drew Hirshfeld: boosting quality and quantity at the USPTO

26 February 2018 Despite concerns over patent quality and with at least one rising backlog, there are positives for the USPTO to focus on, as commissioner for patents Drew Hirshfeld tells WIPR.

Patents

Hirshfeld grants first USPTO director review after Arthrex

4 November 2021 The acting director of the US Patent and Trademark Office Drew Hirshfeld has agreed for the first time to review a final written decision from the Patent Trial and Appeal Board (PTAB) after being given oversight over the board’s rulings in the Supreme Court’s Arthrex decision.

Huawei wins seven-country ban on Netgear routers at the UPC

Propel Fuels seeks top-up damages of $1.2bn in secrets case

Leading US trademark firms and lawyers recognised in new national rankings

Lenovo faces US import ban as ITC sides with Ericsson

Samsara v Motive: ‘Secrets case reads like a pulp novel’

USPTO sanctions attorney over sham Chinese TM filings

Arusha Protocol takes root: Fresh growth for plant variety protection in Africa

Peanut the squirrel (RIP) leaps on the meme coin bandwagon

Hirshfeld defends IPR review authority under Arthrex

More on this story

Editor's picks

Editor's picks

More articles